Gastrointestinal Cancers Symposium (ASCO GI) | Conference

Dr. Uesaka on Gemcitabine vs S-1 in Pancreatic Cancer

January 30th 2013

Katsuhiko Uesaka, MD, PhD, from the Shizuoka Cancer Center Hospital in Japan, discusses the JASPAC-01 study that compared gemcitabine to S-1 in Asian patients with resected pancreatic cancer.

Dr. Hugo Ford on the Phase III COUGAR-02 Study

January 29th 2013

Hugo Ford, MD, from the Addenbrooke's Hospital in Cambridge, UK, describes results from the phase III COUGAR-02 study that examined second-line docetaxel in patients with advanced gastroesophageal adenocarcinoma.

Dr. Abou-Alfa on the Utility of Doxorubicin-Eluting Beads in HCC

January 28th 2013

Ghassan K. Abou-Alfa, MD, from Memorial Sloan-Kettering Cancer Center, discusses a study that examined the utility of doxorubicin-eluting beads in hepatic arterial embolization as a treatment for hepatocellular carcinoma.

2013 Gastrointestinal Cancers Symposium

January 28th 2013

The 2013 Gastrointestinal Cancers Symposium was held at the Moscone West Building, San Francisco, CA, from January 24-26.

Nab-Paclitaxel Plus Gemcitabine Could Be New 'Backbone' of Therapy for Metastatic Pancreatic Cancer

January 28th 2013

Adding nab-paclitaxel to gemcitabine improves survival compared with gemcitabine alone in patients with metastatic pancreatic cancer.

Ramucirumab Moderately Boosts Survival in Advanced Gastric Cancer

January 28th 2013

Ramucirumab significantly extended overall survival as a second-line agent in patients with metastatic gastric or gastroesophageal junction adenocarcinoma that progressed on first-line therapy.

Extended Survival Benefit With Zaltrap Seen in Metastatic Colorectal Cancer

January 28th 2013

Patients with metastatic colorectal cancer whose disease had progressed despite treatment with oxaliplatin experienced an improvement in survival by switching to a regimen of ziv-aflibercept plus FOLFIRI.

Dr. Grothey on the Time Course of Regorafenib-Associated AEs

January 28th 2013

Axel Grothey, MD, from the Mayo Clinic, Rochester, Minnesota, discusses the time course of adverse events following treatment with regorafenib, as observed in the CORRECT study.

Adjuvant S-1 Chemotherapy Bests Gemcitabine in Asian Patients With Pancreatic Cancer

January 25th 2013

Adjuvant chemotherapy with the oral fluoropyrimidine S-1 improved survival versus standard postoperative gemcitabine in Asian patients with pancreatic cancer, according to an interim analysis from a phase III trial conducted in Japan.

Dr. Ramanathan Discusses the Phase III MPACT Trial

January 25th 2013

Ramesh K. Ramanathan, MD, from the Virginia G. Piper Cancer Center, discusses the phase III MPACT study that examined gemcitabine plus nab-paclitaxel in patients with metastatic adenocarcinoma of the pancreas.

Dr. Grady Discusses Molecular Subtypes in Colorectal Cancer

January 25th 2013

William M. Grady, MD, from the Fred Hutchinson Cancer Research Center, discusses results from a study that examined the association of intrinsic subtypes of colorectal cancer with prognosis, chemotherapy response, and other factors.

Gene Profiling of Circulating Tumor Cells May Predict Treatment Response in Pancreatic Cancer

January 25th 2013

A simple blood draw could lead to life-prolonging adjustments in treatment for patients with pancreatic cancer, the authors of a study have found.

Colorectal Cancer Prognosis and Response to Chemotherapy Vary by Molecular Subtype

January 24th 2013

Using a new classification system that categorizes colorectal cancers by tumor gene expression patterns, researchers have determined that tumor prognosis and response to adjuvant chemotherapy in CRC vary according to molecular subtype.

Second-Line Docetaxel Improves Survival and Quality of Life in Patients with Advanced Esophageal and Stomach Cancers

January 23rd 2013

Patients with advanced esophagogastric adenocarcinoma who received docetaxel as a second-line therapy experienced a longer period of overall survival as well as a better quality of life compared with patients who received active symptom control.

Surgery Following Imatinib Boosts Survival for GIST Patients

January 23rd 2013

A retrospective analysis of the potential benefits of surgery following treatment with imatinib (Gleevec) suggests a clear benefit in both OS and PFS in patients with metastatic or recurrent GIST when compared with those who received imatinib therapy alone.